NT-proBNP cardiac value in COVID-19: a focus on the paediatric population

Bshara Sleem,Christophe El Rassi,Rana Zareef,Fadi Bitar,Mariam Arabi

DOI: https://doi.org/10.1017/s1047951124000283

2024-03-28

Cardiology in the Young

Abstract:NT-proBNP is a peptide related to brain natriuretic peptide, a cardiac biomarker and a member of the natriuretic family of peptides. NT-proBNP has demonstrated its clinical utility in the assessment of a wide spectrum of cardiac manifestations. It is also considered a more precise diagnostic and prognostic cardiac biomarker than brain natriuretic peptide. With the appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 virus and the subsequent COVID-19 pandemic, diagnosis of heart implications began to pose an increasing struggle for the physician. Echocardiography is considered a central means of evaluating cardiac disorders like heart failure, and it is considered a reliable method. However, other diagnostic methods are currently being explored, one of which involves the assessment of NT-proBNP levels. In the literature that involves the adult population, significant positive correlations were drawn between the levels of NT-proBNP and COVID-19 outcomes such as high severity and fatality. In the paediatric population, however, the literature is scarce, and most of the investigations assess NT-proBNP in the context of Multiple Inflammatory Syndrome in Children, where studies have shown that cohorts with this syndrome had elevated levels of NT-proBNP when compared to non-syndromic cohorts. Thus, more large-scale studies on existing COVID-19 data should be carried out in the paediatric population to further understand the prognostic and diagnostic roles of NT-proBNP.

pediatrics,cardiac & cardiovascular systems

What problem does this paper attempt to address?

The paper attempts to address the issue of exploring the value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in assessing and predicting cardiac impacts in pediatric COVID-19 patients. Specifically, the paper focuses on the following points:

1. **Relationship between NT-proBNP and cardiac function**: The paper discusses the role of NT-proBNP as a cardiac biomarker in evaluating heart diseases. NT-proBNP has higher stability and a longer half-life compared to brain natriuretic peptide (BNP), making it more sensitive and accurate in diagnosing heart failure.

2. **NT-proBNP levels in adult COVID-19 patients**: Studies have found that NT-proBNP levels are significantly higher in severe COVID-19 patients compared to non-severe patients, and the levels are also significantly higher in deceased patients compared to survivors.

3. **NT-proBNP levels in pediatric patients with Multisystem Inflammatory Syndrome in Children (MIS-C)**: The paper notes that NT-proBNP levels are significantly higher in pediatric patients with MIS-C compared to non-MIS-C patients, and those requiring intensive care have even higher NT-proBNP levels.

4. **Relationship between NT-proBNP and cardiac manifestations**: The paper emphasizes the association between elevated NT-proBNP levels and cardiac injury, particularly in MIS-C and pediatric COVID-19 patients. High NT-proBNP levels suggest potential cardiac injuries such as myocarditis and coronary artery aneurysms.

In summary, the paper aims to explore the potential value of NT-proBNP as a cardiac biomarker in assessing cardiac impacts in pediatric COVID-19 patients through a retrospective analysis of existing literature data, and to provide references for future research.